NEW YORK (Reuters Health) – Patients undergoing percutaneous coronary intervention for acute coronary syndrome initially treated with the synthetic factor Xa inhibitor fondaparinux do not have significantly lower…
NEW YORK (Reuters Health) – While clopidogrel’s effectiveness in the treatment of acute coronary syndromes is affected by a patient’s genotype, the efficacy of ticagrelor is not. Therefore,…
NEW YORK (Reuters Health) – The combination of the dipeptidyl peptidase (DPP)-4 inhibitor alogliptin and the thiazolidinedione pioglitazone effectively reduces HbA1c in patients with type 2 diabetes uncontrolled…
NEW YORK (Reuters Health) – Rapid fluid replenishment “remarkably” improves the detection rate of patent foramen ovale (PFO) by transesophageal echocardiography, a multicenter team reports in the American…
NEW YORK (Reuters Health) – After surgically induced remission of Crohn’s disease, treatment with mesalamine reduces the risk of relapse somewhat; sulfasalazine, however, has no apparent benefit, according…
NEW YORK (Reuters Health) – Among adult patients being treated for hematologic malignancies and who are at high risk for tumor lysis syndrome with hyperuricemia, intravenous rasburicase does…
NEW YORK (Reuters Health) – While contact isolation precautions are recommended for all patients colonized or infected with vancomycin-resistant enterococci (VRE), a European study shows that isolation is…
NEW YORK (Reuters Health) – As long as eligibility criteria are strictly followed, it is safe to let “real world” patients undergoing percutaneous coronary intervention go home on…
NEW YORK (Reuters Health) – If recognized right away, most bile duct injuries related to laparoscopic cholecystectomy should be repaired quickly in a tertiary hepatobiliary center — within…